Brief: Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)
21/01/2026 12:04
Jan 21 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: DAWNZERA™ (DONIDALORSEN) APPROVED IN THE EUROPEAN UNION FOR HEREDITARY ANGIOEDEMA (HAE) IONIS PHARMACEUTICALS INC - ELIGIBLE FOR MILESTONE PAYMENT OF $15 MILLION AND TIERED ROYALTIES OF UP TO 30% ON NET PRODUCT SALES Source text: ID:nBw1hfhy7a Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study